Seres Therapeutics (NASDAQ:MCRB) Stock Rating Lowered by StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

Other equities analysts also recently issued reports about the stock. Chardan Capital reaffirmed a “buy” rating and set a $1.25 price objective on shares of Seres Therapeutics in a report on Wednesday, November 13th. Canaccord Genuity Group restated a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, JPMorgan Chase & Co. lowered shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Stock Performance

Shares of NASDAQ MCRB opened at $0.92 on Wednesday. The firm’s 50-day simple moving average is $0.81 and its 200 day simple moving average is $0.90. The stock has a market cap of $156.23 million, a price-to-earnings ratio of -3.98 and a beta of 2.06. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $2.05.

Hedge Funds Weigh In On Seres Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Seres Therapeutics by 12.1% in the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after acquiring an additional 729,514 shares during the period. Virtu Financial LLC bought a new stake in shares of Seres Therapeutics in the 1st quarter worth approximately $73,000. Providence Wealth Advisors LLC lifted its stake in Seres Therapeutics by 49.5% in the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 25,250 shares during the last quarter. Point72 DIFC Ltd purchased a new position in Seres Therapeutics in the second quarter valued at approximately $64,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Seres Therapeutics during the second quarter valued at $92,000. 59.34% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.